XML 37 R21.htm IDEA: XBRL DOCUMENT v3.25.1

Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Information by segment

The following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s CODM and included in general and administrative costs.

 Schedule of Information by segment

		2024				2023
		Years Ended December 31,
		2024				2023
Compensation to related parties:
Cash-based		$	753,124			$	944,977
Stock-based			418,422				773,203
Patent and licensing legal and filing fees and costs			243,186				978,244
Other consulting and professional fees			735,021				655,854
Insurance expense			434,444				442,976
Other costs and expenses, net			262,360				396,882
Total general and administrative costs		$	2,846,557			$	4,192,136

The following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s CODM, and included in research and development costs.

		2024				2023
		Years Ended December 31,
		2024				2023
Clinical and related oversight costs		$	377,958			$	416,269
Preclinical research focused on development of additional novel anti-cancer compounds			329,438				463,093
Regulatory service costs			18,836				18,738
Total research and development costs		$	726,232			$	898,100

The following table presents a summary of research and development costs for the years ended December 31, 2024 and 2023 based on the respective geographical regions where such costs were incurred.

		2024				2023
		Years Ended December 31,
		2024				2023
United States		$	462,566			$	359,589
Spain			51,022				295,163
China			2,282				17,198
Netherlands			210,362				226,150
Total		$	726,232			$	898,100

The following table presents the Company’s total assets by segment at December 31, 2024 and 2023.

		2024				2023
		December 31,
		2024				2023
Research and development assets		$	39,298			$	78,369
Corporate assets			1,106,205				4,230,251
Total assets		$	1,145,503			$	4,308,620

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration